AstraZeneca has halted a £200m expansion of its Cambridge research site, stalling its £650m UK investment plan.
The Cambridge project, expected to create 1,000 jobs, joins the previously canceled £450m vaccine facility in Merseyside.
An AstraZeneca spokesperson confirmed the pause, citing regular reassessment of investment needs and declined further comment.
Meanwhile, the company plans $50bn in US investments by 2030, including new facilities in Virginia and labs across six states.
The pause follows a week of UK setbacks, including Merck scrapping a £1bn London research centre and laying off 125 scientists.
Sir John Bell warned other pharmaceutical companies are reconsidering UK investments, citing regulatory and economic uncertainties.
Sanofi called for a clearer Treasury plan, stating the UK is currently “not a good place” for drug development.
Eli Lilly also paused its £279m London lab project, reflecting broader industry caution in the UK.
Industry groups urge NHS pricing reform, seeking a lower clawback rate to align with European standards.
AstraZeneca Pauses £200m Cambridge Expansion Amid UK Pharma Setbacks
OMN AI
This article was created with the assistance of OMN AI, the AI-powered editorial platform developed by OMN Group. Every article is reviewed, fact-checked, and approved by a human journalist before publication to ensure accuracy and editorial quality. Learn more at https://omngroup.com
